Disease page

Neuromuscular Disorders

Last updated: 13th Jan 2021

Neuromuscular Disorders are a broad group of conditions that impair muscle function either directly (muscles) or indirectly (nerves or neuromuscular junctions). These disorders cause muscle wasting and can also cause twitching, spasticity or paralysis.

Featured Learning Zones

Learning Zone Homepage

MS: learnings from the pandemic and innovations in patient care

Explore content from the 6th Congress of European Academy of Neurology and the 8th Joint ACTRIMS-ECTRIMS Meeting that took place recently.

Learning Zone Homepage

Spinal Muscular Atrophy

SMA is caused by loss of function mutations or deletions in the SMN1 gene, which results in insufficient levels of the survival of motor neuron (SMN) protein. Find out more here.

Examples of neuromuscular disorders are:

Amyotrophic lateral sclerosis - motor neurone diseases
Multiple sclerosis
Myasthenia gravis
Spinal muscular atrophy

Related news and insights

News

Biogen announces first patient treated in RESPOND phase IV study evaluating Spinraza in patients treated with Zolgensma for spinal muscular atrophy.

Biogen Inc. has announced that the first patient has been treated in the global clinical study, RESPOND. The Phase IV study will examine the clinical benefit and assess the safety of Spinraza (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma (onasemnogene abeparvovec).

2 mins

News

Osmotica Pharmaceuticals plc receives Complete Response Letter from FDA for arbaclofen ER tablets to treat spasticity resulting from multiple sclerosis.

Osmotica Pharmaceuticals plc announced that the FDA has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking approval for the investigational agent arbaclofen extended release ("ER") tablets to treat spasticity resulting from multiple sclerosis.

1 min

News

FDA approves Ocrevus shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis - Genentech/Roche

Genentech, a member of the Roche Group announced that the FDA has approved a shorter two-hour infusion time for Ocrevus (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The approval was based on data from the randomized, double-blind ENSEMBLE PLUS study.

1 min

See all news

Related Journals

Journal

Alemtuzumab depletion failure can occur in multiple sclerosis.

1 mins

Journal

Paediatric multiple sclerosis: a new era in diagnosis and treatment.

1 mins

Journal

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

1 mins

Journal

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.

1 mins

Journal

How people with multiple sclerosis experience the influence of nutrition and lifestyle factors on the disease.

1 mins

Journal

Effectiveness of alternative dose fingolimod for multiple sclerosis.

1 mins

Journal

An update on cladribine for relapsing-remitting multiple sclerosis.

1 mins

Journal

Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.

1 mins

Journal

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.

1 mins

Journal

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.

1 mins

Related Guidelines

Guideline

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

1 mins

Guideline

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use.

1 min

Guideline

Multiple sclerosis in adults: management

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for adults with multiple sclerosis by promoting symptom management...

1 min

See all guidelines